文献速递慢阻肺呼吸危重症与机械通气

体外二氧化碳清除避免慢阻肺急性加重期有创通气:VENT-AVOID随机临床试验

Extracorporeal Carbon Dioxide Removal to Avoid Invasive Ventilation During Exacerbations of Chronic Obstructive Pulmonary Disease: VENT-AVOID Trial - A Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

VENT-AVOID多中心随机试验在慢阻肺急性加重且无创通气失败或脱机困难的患者中比较标准治疗联合静脉-静脉体外二氧化碳清除与单纯标准治疗,因入组缓慢提前终止,实际入组113例(计划180例)。结果显示两组随机化后5天内无呼吸机天数无显著差异(P=0.36),NIV组ECCO2R组全因院内死亡率更高(22% vs 0%,P=0.02)。

要点

  • ECCO2R未改善慢阻肺急性加重患者随机化后5天内无呼吸机天数(P=0.36)。
  • NIV失败亚组中ECCO2R组全因院内死亡率显著更高(22% vs 0%,P=0.02)。
  • 试验因入组缓慢提前终止,实际样本量低于计划。

核心结论

  • 在慢阻肺急性加重患者中,与单纯标准治疗相比,使用ECCO2R未改善随机化后5天内无呼吸机天数。
  • NIV亚组中ECCO2R组全因院内死亡率显著高于标准治疗组,IMV亚组未见差异。

研究设计与样本

  • 多中心随机临床试验,2018-2022年在美国41家机构开展(NCT03255057)。
  • 计划样本量180例,因入组缓慢提前终止,实际入组113例。
  • 随机分为标准治疗联合静脉-静脉ECCO2R组(NIV层n=26,IMV层n=32)与单纯标准治疗组(NIV层n=22,IMV层n=33)。

主要发现

  • 按分层控制后,两组中位VFD-5无显著差异(P=0.36)。
  • NIV层两组中位VFD-5均为5天(中位偏移=0.0;95%CI:0.0-0.0)。
  • IMV层标准治疗组与ECCO2R组中位VFD-5分别为0.25天和2天,中位偏移=0.00(95%CI:0.00-1.25)。
  • NIV层ECCO2R组全因院内死亡率显著更高(22% vs 0%,P=0.02)。
  • IMV层全因院内死亡率两组无差异(17% vs 15%,P=0.73)。

临床怎么用

  • 现有证据不支持在慢阻肺急性加重、NIV失败或脱机困难患者中常规使用ECCO2R以避免有创通气。
  • NIV失败亚组使用ECCO2R时需警惕院内死亡风险升高。

局限性

  • 试验因入组缓慢提前终止,实际入组113例低于计划180例,统计效能受限。
  • 研究结论基于提前终止的样本,亚组分析样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: It is unclear whether extracorporeal CO2 removal (ECCO2R) can reduce the rate of intubation or the total time on invasive mechanical ventilation (IMV) in adults experiencing an exacerbation of chronic obstructive pulmonary disease (COPD). Objectives: To determine whether ECCO2R increases the number of ventilator-free days within the first 5 days postrandomization (VFD-5) in exacerbation of COPD in patients who are either failing noninvasive ventilation (NIV) or who are failing to wean from IMV. Methods: This randomized clinical trial was conducted in 41 U.S. institutions (2018-2022) (ClinicalTrials.gov ID: NCT03255057). Subjects were randomized to receive either standard care with venovenous ECCO2R (NIV stratum: n = 26; IMV stratum: n = 32) or standard care alone (NIV stratum: n = 22; IMV stratum: n = 33). Measurements and Main Results: The trial was stopped early because of slow enrollment and enrolled 113 subjects of the planned sample size of 180. There was no significant difference in the median VFD-5 between the arms controlled by strata (P = 0.36). In the NIV stratum, the median VFD-5 for both arms was 5 days (median shift = 0.0; 95% confidence interval [CI]: 0.0-0.0). In the IMV stratum, the median VFD-5 in the standard care and ECCO2R arms were 0.25 and 2 days, respectively; median shift = 0.00 (95% confidence interval: 0.00-1.25). In the NIV stratum, all-cause in-hospital mortality was significantly higher in the ECCO2R arm (22% vs. 0%, P = 0.02) with no difference in the IMV stratum (17% vs. 15%, P = 0.73). Conclusions: In subjects with exacerbation of COPD, the use of ECCO2R compared with standard care did not improve VFD-5. Clinical trial registered with www.clinicaltrials.gov (NCT03255057).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Duggal, Conrad, Barrett, et al. Extracorporeal Carbon Dioxide Removal to Avoid Invasive Ventilation During Exacerbations of Chronic Obstructive Pulmonary Disease: VENT-AVOID Trial - A Randomized Clinical Trial. Am J Respir Crit Care Med. 2024. PMID: 38261630. doi:10.1164/rccm.202311-2060OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。